Table 3.
Presurgical data
| Control Group | AP Group | AC Group | p value | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (n = 270) | Interruption (n = 7) | Continuing (n = 39) | Total (n = 46) | Interruption (n = 7) | Heparinization (n = 10) | Total (n = 17) | |||||||||
| A | B1 | B2 | B | C1 | C2 | C | A vs. B1 | A vs. B2 | A vs. B | B1 vs. B2 | A vs. C1 | A vs. C2 | A vs. C | C1 vs. C2 | |
| Age mean ± SD | 68.6 ± 6.0 | 67.9 ± 7.4 | 70.2 ± 4.4 | 69.8 ± 5.1 | 68.6 ± 2.9 | 72.4 ± 2.4 | 70.8 ± 3.2 | 0.74 | 0.12 | 0.2 | 0.28 | 0.99 | 0.05 | 0.13 | 0.01 |
| Body mass index(kg/m2) mean ± SD | 23.9 ± 2.8 | 24.0 ± 2.4 | 24.7 ± 3.2 | 24.6 ± 3.1 | 23.2 ± 3.0 | 22.9 ± 2.7 | 23.0 ± 2.8 | 0.9 | 0.09 | 0.11 | 0.6 | 0.52 | 0.25 | 0.2 | 0.82 |
| Serum PSA (ng/mL) mean ± SD | 10.6 ± 10.2 | 6.99 ± 2.58 | 14.9 ± 20.8 | 13.7 ± 19.4 | 9.47 ± 5.29 | 8.06 ± 3.09 | 8.6 ± 4.2 | 0.27 | 0.16 | 0.38 | 0.09 | 0.82 | 0.63 | 0.61 | 0.89 |
| Clinical stage, n (%) | |||||||||||||||
| cT1–T2 | 238 (88.2%) | 7 (100%) | 29 (74.4%) | 36 (78.3%) | 6 (85.6%) | 9 (90%) | 15 (88.2%) | > 0.99 | 0.03 | 0.1 | 0.32 | 0.59 | > 0.99 | > 0.99 | > 0.99 |
| cT3–T4 | 32 (11.8%) | 0 (0%) | 10 (25.6%) | 10 (21.7%) | 1 (14.3%) | 1 (10.0%) | 2 (11.8%) | ||||||||
| Biopsy ISUP grade, n (%) | |||||||||||||||
| 1 | 26 (9.6%) | 4 (57.1%) | 4 (10.2%) | 8 (17.3%) | 2 (28.6%) | 2 (20.0%) | 4 (23.5%) | < 0.01 | 0.56 | 0.3 | 0.04 | 0.06 | 0.62 | 0.28 | 0.45 |
| 2 | 114 (42.6%) | 2 (28.6%) | 20 (51.3%) | 22 (47.8%) | 0(0%) | 4 (40.0%) | 4 (23.5%) | ||||||||
| 3 | 59 (21.9%) | 1 (14.3%) | 4 (10.2%) | 5 (10.9%) | 2 (28.6%) | 2 (20.0%) | 4 (23.5%) | ||||||||
| 4 | 26 (9.6%) | 0 (0%) | 4 (10.2%) | 4 (8.7%) | 0 (0%) | 1 (10.0%) | 1 (5.9%) | ||||||||
| 5 | 44 (16.3%) | 0 (0%) | 7 (17.9%) | 7 (15.2%) | 3 (42.9%) | 4 (40.0%) | 4 (23.5%) | ||||||||
| ASA physical status classification | |||||||||||||||
| I | 40 (15.3%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (10.0%) | 1 (5.9%) | 0.01 | < 0.01 | < 0.01 | > 0.99 | 0.44 | < 0.01 | < 0.01 | 0.04 |
| II | 219 (80.8%) | 5 (71.4%) | 27 (69.2%) | 32 (69.6%) | 7 (100%) | 4 (40.0%) | 11 (64.7%) | ||||||||
| III | 11 (3.7%) | 2 (28.6%) | 12 (30.8%) | 14 (30.4%) | 0 (0%) | 5 (50.0%) | 5 (29.4%) | ||||||||
AP: antiplatelet, AC: anticoagulant, PSA prostate-specific antigen, ISUP International Society of Urological Pathologists, ASA American Society of Anesthesiologists